This Science News Wire page contains a press release issued by an organization and is provided to you "as is" with little or no review from Science X staff.

Long-term immune response to Sputnik-V COVID vaccine

October 26th, 2021 Rufina Gimaletdinova, Yury Nurmeev
Long-term immune response to Sputnik-V COVID vaccine
Analysis of cytokines in SputnikV vaccinated and convalescent COVID-19 sera. A and B Serum samples before (D0), after vaccination on D21 and D42 (21 and 42 days after the first dose of vaccine, respectively) as well as 42.0 ± 11.1 days (median ± SEM) after COVID-19 convalescence were used to analyze 48 cytokines (Bio-Plex Pro Human Cytokine 48-plex Screening Panel (12007283, BioRad, Hercules, USA)). Each sample was tested in triplicate. Data were analyzed with MasterPlex CT control software and MasterPlex QT analysis software (MiraiBio, San Bruno, CA, USA). Data are presented as a Log2 difference between a vaccinated or convalescent sample and controls. Cytokines IL-1β, IL-18, CCL27, CXCL1 and VEGF did not differ significantly and were not included in the figure *—Significant difference between D21 and D0; *—significant difference between D42 and D0; *—significant difference between COVID-19 convalescent and D0. Credit: Kazan Federal University
A joint Russian-British-Indian research appeared in International Journal of Molecular Sciences.

The contributors are Kazan Federal University, Kazan State Medical Academy, Thapar Institute of Engineering and Technology, and the University of Liverpool.

Sputnik-V, a COVID vaccine from Gamaleya Institute, Russia, was the first nationally registered vaccine in the world and is currently in use in over 50 countries. It has shown good efficacy with a relatively low number of serious side effects.

The research aimed at finding out the specifics of immune reactions to Sputnik-V in inoculated populations in Kazan (the city where Kazan Federal University is situated).

The studies showed that even the first dose can initiate an immune response, and the second dose provokes a more robust response which can be detected three months after the administration. The reaction involves both antibodies and T-cell immunity. Furthermore, the team proved that the immune response in the inoculated and those who recovered from COVID is basically the same—which means that the vaccine is effective against the local virus variants. The takeaway is supported by data from the localization of immunogenic epitopes and the analysis of virus mutations.

Co-author, KFU Professor Albert Rizvanov comments, "Sputnik-V elicits both antibody and T-cell immunity. In this paper, we specifically studied a three-month timeframe after vaccination. At this point in time, the response was strong, which can prove the existence of long-term immunity."

The study was approved by Kazan University's Local Ethics Committee.

More information:
Long Term Immune Response Produced by the SputnikV Vaccine

Provided by Kazan Federal University

Citation: Long-term immune response to Sputnik-V COVID vaccine (2021, October 26) retrieved 3 December 2021 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.